Xgene Pharmaceutical's XG005 showed a statistically significant reduction in post-surgical pain compared to placebo in patients undergoing bunionectomy.
The FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for treating moderate to severe acute pain in adults, offering a safer alternative to opioids.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.